Compare MERC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MERC | IMRN |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.7M |
| IPO Year | 2005 | 2016 |
| Metric | MERC | IMRN |
|---|---|---|
| Price | $0.25 | $0.82 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $0.13 | N/A |
| AVG Volume (30 Days) | ★ 25.4M | 16.7K |
| Earning Date | 11-05-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | N/A |
| Revenue This Year | $0.85 | $16.39 |
| Revenue Next Year | $11.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $0.12 | $0.68 |
| 52 Week High | $2.85 | $1.99 |
| Indicator | MERC | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 33.29 |
| Support Level | $0.14 | $0.73 |
| Resistance Level | $0.41 | $0.89 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 52.79 | 27.32 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.